KBP-7072 is under clinical development by KBP Biosciences and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect KBP-7072’s likelihood of approval (LoA) and phase transition for Acinetobacter Infections took place on 07 Sep 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their KBP-7072 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
KBP-7072 (Bipyrocycline) is under development for the treatment of infections caused by multi-drug resistant bacterial strains such as acute bacterial skin and skin structure infections (ABSSI) caused by methicillin-resistant Staphylococcus aureus (MRSA), community-acquired bacterial pneumonia (CABP) due to penicillin-resistant Streptococcus pneumoniae (PRSP), complicated intraabdominal infections (cIAI) caused by vancomycin-resistant Enterococcus (VRE) and Acinetobacter species. It acts by targeting 30S ribosomal subunit (30S RNA). The drug candidate is an aminomethylcycline antibiotic, administered orally and intravenously. KBP-7072 is a new chemical entity (NCE).
KBP Biosciences overview
KBP Biosciences is a biopharmaceutical company that discovers, develops and commercializes small molecule drugs to treat cardiorenal and infectious diseases. The company’s lead product candidate KBP-5074, a non-steroidal mineralocorticoid receptor antagonist (MRA) is used for the treatment of uncontrolled hypertension in patients with chronic kidney diseases. KBP Biosciences is also investigating KBP-7072, a tetracycline formulation targeting multi drug resistant bacteria infections; KPB-7026 against eosinophilic asthma; KBP-8017, a multi kinase inhibitor to treat fibrosis caused due to radiotherapy; and KBP-7909 drug targeting gram negative bacterial infections. Its proprietary discovery platform helps in estimating pharmacokinetics/pharmacodynamics (PK/PD) and toxicology across various drug candidates. The company has operations in the US. KBP Biosciences is headquartered in Shanghai, China.
Quick View KBP-7072 LOA Data
|Highest Development Stage|